Closing out an observational study involves several key steps to ensure that all study activities are concluded properly, and data integrity is maintained. Here are the typical activities involved:
[1] Data Lock and Validation: The first step in the study closeout process is to ensure all data is collected, cleaned, and ready for analysis. This involves resolving any outstanding queries, performing a final quality control check on the data, and then locking it for final analysis. This step also requires validation of data by checking the accuracy and consistency of the data collected.
[2] Disposition of Study Materials: Any remaining study materials, such as unused data collection forms or materials used for measurements, need to be disposed of appropriately. Any biological samples collected during the study also need to be handled as per the protocol and regulatory guidelines, which could mean returning, destroying, or continuing to store them, as agreed.
[3] Final Report Preparation: After data is locked and validated, the study team will analyse the data and prepare a final study report. This report content and format should follow regulatory requirements where applicable e.g., EU PASS Report.
[4] Archiving Study Documents: All study documents, including the study protocol, data collection forms, consent forms, and correspondence, should be properly archived according to the regulatory requirements and the company’s SOPs.
[5] Site Closeout Visits: If the study was performed across multiple sites, each site may need a closeout visit. These visits serve to confirm that all necessary activities have been completed, including data collection, storage or destruction of study materials, and archiving of site documents.
[6] Contract Closure: Finally, any contracts related to the study, such as those with study sites or service providers, need to be formally closed. This could involve confirming that all deliverables have been met, all payments have been made, and all obligations are fulfilled.
[7] Notification of End of Study: It’s important to inform the relevant ethical review board (IRB/REC) or regulatory authority that the study has ended, and provide them with a summary of the study’s findings, if required.
[8] Communicating Results: Depending on the nature of the study and its sponsorship, the results may need to be communicated to a variety of stakeholders. This could include the sponsor, study participants, health authorities, and potentially the wider scientific community through publications.
These activities help ensure that the study is closed out in a systematic and organized manner, which is critical for compliance, data integrity, and future use or inspection of the study data and materials. The exact nature and sequence of the activities may vary depending on the specifics of the study, the regulatory framework, and the procedures established by the sponsor.
Share this story...
Real World Evidence (RWE) 101 – Registry vs Registry-Based Study
RWE 101 - Registry vs Registry-Based Study In the context of real-world evidence, a registry is a collection of data on a particular disease, medical condition, or [...]
Real World Evidence (RWE) 101 – Pregnancy Registries
RWE 101 - Pregnancy Registries A pregnancy registry is a type of real-world evidence collection system that collects data from pregnant women who have been exposed to [...]
Real World Evidence (RWE) 101 – Diversity
RWE 101 - Diversity Diversity in the context of real-world research refers to the inclusion of individuals from different backgrounds, including but not limited to race, ethnicity, gender, [...]
Real World Evidence (RWE) 101 – The Patient Voice
RWE 101 - The Patient Voice The patient voice refers to the perspectives, opinions, and experiences of patients and their families or caregivers in the context of [...]
Real World Evidence (RWE) 101 – ISPE GPP
RWE 101 - ISPE GPP The International Society of Pharmacoepidemiology (ISPE) Good Pharmacoepidemiology Practices (GPP) provides guidance for the conduct and reporting of pharmacoepidemiologic studies. The key [...]
Real World Evidence (RWE) 101 – EMA Good Pharmacovigilance Practices (GVPs)
RWE 101 - EMA Good Pharmacovigilance Practices (GVPs) The European Medicines Agency's (EMA) Good Pharmacovigilance Practices (GVPs) provide a framework for the monitoring and reporting of adverse drug [...]







